Teleflex Incorporated (NYSE:TFX) had its target price lifted by Deutsche Bank AG from $192.00 to $213.00 in a research report released on Wednesday morning. They currently have a buy rating on the medical technology company’s stock.
Several other equities research analysts have also weighed in on TFX. Zacks Investment Research upgraded shares of Teleflex from a hold rating to a buy rating and set a $217.00 price objective on the stock in a research note on Tuesday, March 14th. Jefferies Group LLC upgraded shares of Teleflex from a hold rating to a buy rating and increased their price objective for the stock from $155.00 to $190.00 in a research note on Friday, January 6th. Barclays PLC reiterated a buy rating and set a $205.00 price objective on shares of Teleflex in a research note on Wednesday, March 1st. Leerink Swann increased their price objective on shares of Teleflex from $151.00 to $177.00 and gave the stock a market perform rating in a research note on Monday, February 13th. Finally, Stephens upgraded shares of Teleflex from an equal weight rating to an overweight rating in a research note on Friday, February 24th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $198.71.
Teleflex (NYSE:TFX) opened at 195.46 on Wednesday. The company’s 50 day moving average price is $183.06 and its 200 day moving average price is $167.45. The firm has a market capitalization of $8.78 billion, a P/E ratio of 39.22 and a beta of 0.93. Teleflex has a 12 month low of $136.53 and a 12 month high of $198.89.
Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 23rd. The medical technology company reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.04. The firm had revenue of $513.90 million for the quarter, compared to analyst estimates of $502.64 million. Teleflex had a net margin of 15.09% and a return on equity of 15.66%. Teleflex’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 earnings per share. Analysts anticipate that Teleflex will post $8.10 EPS for the current year.
Your IP Address:
The company also recently announced a quarterly dividend, which was paid on Wednesday, March 15th. Shareholders of record on Friday, March 3rd were given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend was Wednesday, March 1st. Teleflex’s dividend payout ratio (DPR) is 23.49%.
In other Teleflex news, Director Jeffrey A. Graves sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $160.57, for a total value of $802,850.00. Following the completion of the transaction, the director now owns 13,022 shares in the company, valued at approximately $2,090,942.54. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.15% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of TFX. Acrospire Investment Management LLC raised its stake in shares of Teleflex by 71.4% in the third quarter. Acrospire Investment Management LLC now owns 1,200 shares of the medical technology company’s stock valued at $202,000 after buying an additional 500 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new stake in shares of Teleflex during the third quarter valued at about $211,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Teleflex by 14.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,267 shares of the medical technology company’s stock valued at $213,000 after buying an additional 160 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Teleflex by 103.6% in the third quarter. Tower Research Capital LLC TRC now owns 1,360 shares of the medical technology company’s stock valued at $229,000 after buying an additional 692 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Teleflex by 7.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,450 shares of the medical technology company’s stock valued at $240,000 after buying an additional 97 shares in the last quarter. Hedge funds and other institutional investors own 93.02% of the company’s stock.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors.
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.